Cochrane puts multimorbidity and renal blood pressure control in the same frame
Cochrane’s latest curated collection places multiple chronic conditions at the center of a problem that is becoming harder to ignore in everyday practice. Aging populations, lifestyle-related risk, and long-term infections are expanding the number of patients who arrive with more than one chronic disease at the same time, while social and economic disadvantage continues to widen the gap in who carries that burden. The collection is not a single trial or one narrow question. It is a set of reviews assembled around the practical problem clinicians face when one disease target collides with another, and when treatment decisions have to account for frailty, nutritional status, falls, diabetes, kidney disease, and cardiovascular risk all at once.
One review in the collection stands out for its immediate bedside relevance: blood pressure targets for hypertension in people with chronic renal disease. Hypertension and chronic kidney disease are tightly linked biologically. Elevated intraglomerular pressure can worsen renal injury, while progressive loss of kidney function can intensify blood pressure dysregulation through sodium retention, vascular stiffness, and neurohormonal activation. In that setting, the target chosen for treatment is not a technical detail. It determines how aggressively clinicians push therapy, how closely they monitor for adverse effects, and how they balance kidney protection against dizziness, electrolyte disturbance, and treatment burden.
The review title alone signals why the question matters. People with chronic renal disease often sit at the intersection of cardiovascular and metabolic risk, and they are frequently taking multiple medications already. A lower blood pressure target may theoretically reduce downstream vascular injury and slow kidney decline, but a more aggressive target can also magnify the risk of symptomatic hypotension or treatment intolerance in patients who are already physiologically fragile. Those competing pressures are exactly why evidence synthesis matters here. Clinical teams need a clear reading of what the trials do and do not support before they intensify therapy in a population where small changes in perfusion can have outsized consequences.
The collection also includes reviews on glucagon-like peptide 1 receptor agonists and DPP-4 inhibitors for people with chronic kidney disease and diabetes, which reflects how often kidney disease now coexists with diabetes in routine care. It includes colchicine for secondary prevention of cardiovascular events, a reminder that cardiovascular risk reduction remains central when multiple chronic conditions cluster in the same patient. Other reviews address falls prevention in older people, both in the community and in care facilities, along with nutritional interventions for hospitalized older adults at nutritional risk. These are not isolated geriatric topics. They are the recurring consequences of multimorbidity itself: weakness, falls, undernutrition, polypharmacy, and impaired reserve.
A single disease model no longer fits many of the patients entering primary care, nephrology, cardiology, or inpatient geriatric services.
The review on blood pressure targets for hypertension in people with chronic renal disease sits at a particularly sensitive junction because kidney disease often changes the meaning of standard cardiovascular guidance. Blood pressure thresholds that look straightforward on paper can become less certain once renal function is impaired, albuminuria is present, or the patient is elderly and susceptible to orthostatic symptoms. Clinicians then need more than a number. They need a defensible target that reflects outcome data, tolerability, and the realities of long-term adherence. In practical terms, this is where evidence reviews can prevent both undertreatment and overtreatment.
The broader collection also makes a quiet but important equity point. People with multimorbidity are not affected evenly. Socially and economically disadvantaged populations bear a disproportionate share of chronic disease, and that increases the chance of delayed diagnosis, fragmented follow-up, and higher treatment complexity. A review collection focused on improving care for multiple chronic conditions therefore carries implications beyond any single disease pathway. It speaks to how health systems organize prevention, medication management, rehabilitation, nutrition support, and fall prevention for patients who do not present with one tidy diagnosis.
The falls reviews are a clear example. In older adults, preventing falls is not only about avoiding injury. It also intersects with medication review, muscle strength, balance, environmental safety, cognitive vulnerability, and the consequences of blood pressure treatment itself. A patient with chronic kidney disease and hypertension who is being treated to a lower pressure target may also be the same patient at risk of falling, especially if frail, undernourished, or taking several antihypertensive agents. The question is not whether one domain matters more than another. The question is how to manage them together without creating new harm while attempting to reduce long-term risk.
The curator’s choice to center this collection on multiple chronic conditions is clinically sensible because the problem is expanding across nearly every specialty. Diabetes care now overlaps with renal protection. Cardiovascular prevention overlaps with anti-inflammatory treatment. Geriatric medicine overlaps with nutrition and mobility. Hypertension management overlaps with falls risk. In that environment, a review on blood pressure targets in chronic renal disease is more than a narrow nephrology update. It is a model of how evidence must be interpreted when comorbidity changes both the expected benefit and the likely cost of treatment.
Cochrane lists the renal blood pressure review among newer updates in the collection, alongside reviews published in 2025 and 2026 on related chronic disease questions. The collection does not provide the outcome findings in this page view, but it does establish the clinical priorities driving the evidence agenda: how to treat patients with overlapping chronic illnesses, how to reduce avoidable harm, and how to make targets meaningful in populations where renal, cardiovascular, metabolic, and geriatric risks are inseparable. What remains unresolved on this page is not the importance of the question, but the precise balance of benefit and risk each review will support for day-to-day decision-making.